NeoGenomics Unveils RaDaR ST Liquid Biopsy MRD Assay for Solid Tumor Detection
NeoGenomics Inc. has announced the presentation of new research at the ISLB Annual Congress 2025, showcasing results from the RaDaR ST Bridging Study, which indicates high concordance between its RaDaR ST and RaDaR 1.0 assays for detecting molecular residual disease in solid tumors. The company will also discuss its NextGen whole genome-based MRD research program and findings from four additional studies. The RaDaR ST assay is expected to launch commercially in Q1 2026.
NeoGenomics Inc. has announced that it will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025. The company will showcase results from the RaDaR ST Bridging Study, which demonstrates high concordance between its RaDaR® ST and RaDaR® 1.0 assays for detecting molecular residual disease (MRD) in solid tumors. Additional presentations will highlight the progress of NeoGenomics’ NextGen whole genome-based MRD research program and findings from four other studies focused on liquid biopsy and comprehensive genomic profiling across various solid tumor types. The expected commercial launch of the RaDaR ST assay is planned for the first quarter of 2026. The results from these studies will be presented at the upcoming ISLB 2025 congress. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251030563337) on October 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
